• Facebook
  • Twitter
  • LinkedIn
  • Google +
  • RSS

Pharma sales surpassed $1 trillion in 2014

5 August 2015  •  Author: Victoria White

The Intellectual Property and Science business of Thomson Reuters has released its 2015 CMR Pharmaceutical R&D Factbook, the biopharmaceutical industry’s leading resource of global R&D trends.


Despite concerns around declines in R&D, the analysis identifies a surge in global sales with 2014’s $1 trillion milestone and forecasts sales to reach $1.3 trillion by 2018. It also reveals a positive shift in new molecular entities (NMEs) with 46 launches in 2014; the highest in over a decade.

The study underscores a promising industry outlook with increases in sales and NME launches and with shifting trends in R&D pipeline volume. One third of 2014 NME launches were for rare indications while more than 65% were speciality drugs for the treatment of anti-cancer, HCV and HIV. Anti-cancer development continues to attract the highest amount of investments across all therapeutic areas; with the majority of recent launches receiving orphan drug status from regulatory authorities.

Pharma industry improving ability to ‘fail fast and cheaply’

The study also shows that across the industry there has been a decline in pipeline volumes are early phases. Phase III pipeline volumes are steadily growing due to the improved ability to “fail fast and cheaply,” increasing the speed of potentially successful compounds through development.

Since 2003, the CMR Pharmaceutical R&D Factbook has been built in collaboration with leading global pharma companies to assess productivity and to provide insights to strengthen planning and the effectiveness of R&D. It is based on proprietary, primary sources, competitive intelligence, and public sources covering key trends across the landscape, including R&D pipeline volume, success rates, cycle times, regional comparisons, therapeutic areas, and generics.

“This is an extraordinary year for pharma,” said Basil Moftah, president, Thomson Reuters IP & Science. “Not only do  the critical insights provided by the Factbook challenge negative perceptions, but it demonstrates this industry’s continued commitment to creating and  employing  innovative solutions to tackle its largest hurdles.”

Comments are closed.


Webinar: Use of MicroNIR to optimise fluid bed drying and to reduce waste at tablet compressionFIND OUT MORE
+ +